Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery (Q34687101)

3 August 2017

title

Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery (English)

1 reference

3 August 2017

0 references

Olfa Derbel

1

1 reference

3 August 2017

Qing Wang

2

1 reference

3 August 2017

Françoise Desseigne

3

1 reference

3 August 2017

Michel Rivoire

4

1 reference

3 August 2017

Pierre Meeus

5

1 reference

3 August 2017

Patrice Peyrat

6

1 reference

3 August 2017

Mattia Stella

7

1 reference

3 August 2017

Isabelle Martel-Lafay

8

1 reference

3 August 2017

Anne-Isabelle Lemaistre

9

1 reference

3 August 2017

Christelle de La Fouchardière

10

1 reference

3 August 2017

language of work or name

English

0 references

publication date

23 April 2013

1 reference

3 August 2017

1 reference

3 August 2017

volume

13

1 reference

3 August 2017

page(s)

200

1 reference

Phospho-ERK and AKT status, but not KRAS mutation status, are associated with outcomes in rectal cancer treated with chemoradiotherapy.

3 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640970

Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640970

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640970

7 July 2018

Global cancer statistics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640970

Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640970

Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640970

PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640970

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640970

Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640970

Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640970

Chemotherapy with preoperative radiotherapy in rectal cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640970

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640970

Preoperative versus postoperative chemoradiotherapy for rectal cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640970

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640970

Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640970

Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640970

Ras oncogene expression as a prognostic indicator in rectal adenocarcinoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640970

Recurrence and survival after total mesorectal excision for rectal cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640970

Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases.

7 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-200

Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-200

Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-200

Biochemical and functional characterization of germ line KRAS mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-200

Genetics: Predictive value of KRAS mutations in chemoresistant CRC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-200

Local recurrence in rectal cancer can be predicted by histopathological factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-200

Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-200

KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-200

Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-200

Do rectal cancer patients with PIK3CA mutations benefit from preoperative radiotherapy with regard to local recurrences?

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-200

Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-200

Molecular genetic changes associated with colorectal carcinogenesis are not prognostic for tumor regression following preoperative chemoradiation of rectal carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-200

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640970

Ras mediates radioresistance through both phosphatidylinositol 3-kinase-dependent and Raf-dependent but mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-independent signaling pathways.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640970

Pre- or postoperative radiotherapy in rectal and rectosigmoid carcinoma. Report from a randomized multicenter trial

26 October 2018

1 reference

12 December 2020

PIK3CA mutation is predictive of poor survival in patients with colorectal cancer

1 reference

12 December 2020

Patients with initially unresectable colorectal liver metastases: is there a possibility of cure?

1 reference

12 December 2020

PIK3CA Mutations Predict Local Recurrences in Rectal Cancer Patients

1 reference

12 December 2020

Downstaging without complete pathologic response after neoadjuvant treatment improves cancer outcomes for cIII but not cII rectal cancers

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2407-13-200

1 reference

Dimensions Publication ID

3 August 2017

0 references

1 reference

3 August 2017

1 reference